Ebola Virus Antibodies
Ebola virus antibodies, supplied by The Native Antigen Company, are raised against our own recombinant Ebola virus-like particles.
Ebola virus disease (EVD) is a severe disease caused by several species of Ebolavirus (EBOV), in the family Filoviridae. Prior to 2007, four species of EBOV had been identified, with two (Zaire ebolavirus and Sudan ebolavirus) having caused significant disease outbreaks in humans. The presence of a fifth EBOV virus species, Bundibugyo ebolavirus (BEBOV) was identified after an outbreak of EVD in the Bundibugyo District of western Uganda in 2007. Outbreaks of EVD are associated with person-to-person transmission after the virus is introduced into humans from a zoonotic reservoir. During outbreaks the virus is commonly transmitted through direct contact with infected individuals or their bodily fluids. The onset of EVD is associated with nonspecific clinical symptoms, including fever, myalgia, headache, abdominal pain, nausea, vomiting, and diarrhoea. In the later stages of disease, overt haemorrhage has been reported in up to 50% of cases (MacNeil, A).
The Zaire subtype of the Ebola virus family is currently the most important in relation to outbreaks of disease in humans. This subtype has been responsible for the largest ever outbreak of EVD, which started in West Africa in 2014 and came to an end in early 2016.
The Native Antigen Company supply Ebola virus antibodies and highly purified viral antigens to support researchers working with Ebola virus.
- MacNeil, A et al. (2010). Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda. Emerg Infect Dis. 16(12): 1969–1972.
We hold good stocks of all our antigens to ensure a rapid delivery service worldwide. We like to be in touch with our customers so please drop us a line or give us a call on +44 (0)1865 595230. To place an order, please email email@example.com and for further information including price inquiries, bulk preparations and contract services email: firstname.lastname@example.org.